555
Participants
Start Date
January 31, 1997
Primary Completion Date
February 13, 2001
Study Completion Date
December 15, 2008
marimastat
10 mg PO BID
Placebo
10 mg PO BID
Cross Cancer Institute, Edmonton
Penticton Regional Hospital, Penticton
British Columbia Cancer Agency, Vancouver
British Columbia Cancer Agency - Vancouver Island Cancer Centre, Victoria
CancerCare Manitoba, Winnipeg
Moncton Hospital, Moncton
Doctor Leon Richard Oncology Centre, Moncton
Saint John Regional Hospital, Saint John
Newfoundland Cancer Treatment and Research Foundation, St. John's
Nova Scotia Cancer Centre, Halifax
William Osler Health Centre, Brampton
Northeastern Ontario Regional Cancer Centre, Sudbury, Greater Sudbury
Hamilton Regional Cancer Centre, Hamilton
Trillium Health Centre, Mississauga
Credit Valley Hospital, Mississauga
York County Hospital, Newmarket
North York General Hospital, Ontario, North York
Lakeridge Health Oshawa, Oshawa
Ottawa Regional Cancer Centre - General Campus, Ottawa
Peterborough Oncology Clinic, Peterborough
Hotel Dieu Health Sciences Hospital - Niagara, St. Catharines
Northwestern Ontario Regional Cancer Centre, Thunder Bay, Thunder Bay
Toronto East General Hospital, Toronto
Toronto Sunnybrook Regional Cancer Centre, Toronto
St. Michael's Hospital - Toronto, Toronto
Mount Sinai Hospital - Toronto, Toronto
Toronto General Hospital, Toronto
Saint Joseph's Health Centre - Toronto, Toronto
Humber River Regional Hospital, Weston
Cancer Care Ontario - Windsor Regional Cancer Centre, Windsor
CHUS-Hopital Fleurimont, Fleurimont
Centre Hospitalier de l'Universite de Montreal, Montreal
McGill University, Montreal
Hopital Du Sacre-Coeur de Montreal, Montreal
Hopital du Saint-Sacrament, Quebec, Québec
L'Hopital Laval, Ste-Foy
Allan Blair Cancer Centre, Regina
Saskatoon Cancer Centre, Saskatoon
Lead Sponsor
NCIC Clinical Trials Group
NETWORK